Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-cL blocking agents in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 27, Issue 2, 2009, Pages 333-336

  Benucci, M ^a,e   Manfredi, M ^b   Saviola, G ^c   Baiardi, P ^d   Campi, P ^e  

^a Rheumatology Unit   (Italy)

^b lmmunology and Allergology Laboratory

^c Rheumatology and Rehabiliation Unit IRCCS S Maugeri   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Anti TNF alpha; Atopy; Hypersensitivity reactions

Indexed keywords

ADALIMUMAB; ALLERGEN; CORTICOSTEROID; ETANERCEPT; IMMUNOGLOBULIN E; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

ANGIONEUROTIC EDEMA; ATOPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LARYNX SPASM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THORAX PAIN; URTICARIA;

ARTHRITIS, RHEUMATOID; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; MALE; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67249097204     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. DESAI SB, FURST DC: Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-90.
2. CHEIFETZ A, SMEDLEY M, MARTIN S et at.: The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 13 15-24.
3. DORE RK. MATHEWS S, SCHLECHTMAN J et at.: The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
4. PICHLER WJ, CAMP! P: Adverse side effects to biological agents. In PICHLER WJ (Ed.) Drug Hypersensitivity. Basel: Karger; 2007, 160-74.
5. WOLBINK GJ, VIS M. LEMS W et at.: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
6. MAINI R, ST CLAIR EW, BREEDVELD F et at.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
7. CAMPI P. BENUCCI M, MANFREDI M, DEMOLY P: Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007; 7: 393-403.
8. SANY J, KAISER Mi, JORGENSEN C, TRAPE G: Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheurn Dis 2005; 64: 1647-9.
9. RIEGERT-JOHNSON DL, GODFREY JA, MYERS JL, HUBMAYR RD. SANDBORN Wi, LOFTUS cv its: Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002; 8: 186-91.
10. VULTAGGIO A, MATUCCI A, PARRONCHI F, ROSSI O, ROMAGNANI S. MAGGI E: Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacot 2008; 21: 367-74.
11. ZELTSER R, VALLE L, TANCK C. HOLYST MM, RITCHLIN C, GASPARI AA: Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fe fusion protein. Arch Dermatol 2001; 137: 893-9.
12. MORELAND LW, SCHIFF MH, BAUM- GARTNER SW et at.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
13. WINFIELD H, LAIN E, HORN T, HOSKYN J: Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol 2006; 142: 218-20.
14. BENUCCI M, MANFREDI M, CAMPI P: Injection site reaction to TNF alpha blocking agents with positive skin test. Allergy 2008; 63: 138-9.
15. MEASE PJ, GLADMAN DD, RITCHLIN CT et al.: Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89.
16. WEINIBLATT ME, KEYSTONE CC, FURST DE et at.: Adalimumab. a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
17. BENNETT AN. WONG M, ZAIN A, PANAYI G. KIRKHAM B: Adalimumab-induced asthma. Rheumatology (Oxford) 2005; 44: 1199-2000.
18. GEORGE SJ. ANDERSON HL, HSU S: Adalimumab-induced urticaria. Dermatol Online J 2006; 12: 4.
19. JARRETF SJ. CUNNANE G. CONAGHAN PG et al.: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003 Oct; 30: 2287-91.
20. HOUTMAN PM, JANSEN TL, BLANKEN R: Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? J Clin Rheumatol 2006: 12: 321-2.
21. SÀNCHEZ-CANO D. CALLEJAS-RUBIO JL. ORTEGO-CENTENO N. RUIZ-VILLAVERDE R: Urticaria and angioedema In a patient with Behçet's disease treated with adalimumab. Clin Exp Rheumatol 2006: 24: S 128.
22. NIKAS SN. VOULGARI PV. DROSOS AA: Urticaria and angioedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007: 26: 787.